High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
116.42M
+19.64%
0.080
-120.51%
112.83M
+14%
0.042
-520%
124.05M
+9.8%
0.108
+260%
Estimates Revision
The market is revising Upward the revenue expectations for Artivion, Inc. (AORT) for FY2025, with the revenue forecasts being adjusted by 0.68% over the past three months. During the same period, the stock price has changed by 4.41%.
Revenue Estimates for FY2025
Revise Upward
+0.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+74.68%
In Past 3 Month
Stock Price
Go Up
+4.41%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 51.71 USD with a low forecast of 40.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 45.410
Low
40.00
Averages
51.71
High
58.00
Current: 45.410
Low
40.00
Averages
51.71
High
58.00
Ladenburg
Jeffrey Cohen
Neutral
maintain
$38 -> $40
2025-11-07
Reason
Ladenburg
Jeffrey Cohen
Price Target
$38 -> $40
2025-11-07
maintain
Neutral
Reason
Ladenburg analyst Jeffrey Cohen raised the firm's price target on Artivion to $40 from $38 and keeps a Neutral rating on the shares.
Oppenheimer
Oppenheimer
Outperform
maintain
$40 -> $50
2025-11-07
Reason
Oppenheimer
Oppenheimer
Price Target
$40 -> $50
2025-11-07
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Artivion to $50 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 revenue of $113.4M, +16% year-over-year, above its/consensus estimate of $112M/$110M. FY25 revenue guidance was raised, now $439M-$445M, and management remains confident about double-digit top-line growth.
Lake Street
Buy
maintain
$45 -> $55
2025-11-07
Reason
Lake Street
Price Target
$45 -> $55
2025-11-07
maintain
Buy
Reason
Lake Street raised the firm's price target on Artivion to $55 from $45 and keeps a Buy rating on the shares after Q3 revenue outperformed and management stated they remains confident in the ability to deliver double digit revenue growth while growing AEBITDA twice as fast in 2026.
Stifel
Rick Wise
Buy
maintain
$46 -> $55
2025-11-07
Reason
Stifel
Rick Wise
Price Target
$46 -> $55
2025-11-07
maintain
Buy
Reason
Stifel analyst Rick Wise raised the firm's price target on Artivion to $55 from $46 and keeps a Buy rating on the shares, noting that Q3 quarterly growth of about 16% year-over-year was "the fastest in several years." The firm says its 2026 revenue growth projection of $492M would be up about 11% from 2025.
Citizens JMP
Outperform
maintain
$47 -> $53
2025-11-07
Reason
Citizens JMP
Price Target
$47 -> $53
2025-11-07
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Artivion to $53 from $47 and keeps an Outperform rating on the shares. Artivion's Q3 results reflected a beat and raise, as well as positive incremental product and clinical updates, the analyst tells investors in a research note. The firm continues to be impressed by Artivion's strong fundamentals, dependable base business, complementary advanced stent graft division, and notable EBITDA growth and margin profile.
Canaccord
William Plovanic
Buy
maintain
$50 -> $51
2025-11-07
Reason
Canaccord
William Plovanic
Price Target
$50 -> $51
2025-11-07
maintain
Buy
Reason
Canaccord analyst William Plovanic raised the firm's price target on Artivion to $51 from $50 and keeps a Buy rating on the shares. The firm said Artivion reported a strong Q3, with a beat fueled by growth in both the aortic stent graft business and On-X. The company raised 2025 guidance to reflect the Q3 momentum and provided some 2026 commentary to level set expectations for investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Artivion Inc (AORT.N) is 126.84, compared to its 5-year average forward P/E of 135.55. For a more detailed relative valuation and DCF analysis to assess Artivion Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
135.55
Current PE
126.84
Overvalued PE
1323.78
Undervalued PE
-1052.69
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
20.96
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
26.56
Undervalued EV/EBITDA
15.36
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.55
Current PS
0.00
Overvalued PS
3.33
Undervalued PS
1.78
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AORT News & Events
Events Timeline
(ET)
2025-11-06
16:14:50
Artivion increases FY25 revenue forecast to $439M-$445M, up from $435M-$443M
2025-11-06
16:13:02
Artivion announces Q3 non-GAAP EPS of 16 cents, surpassing consensus estimate of 15 cents.
2025-11-06
08:07:20
Artivion reports first patient treated in ARTIZEN pivotal trial
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/04b0c5811de3f0f018f61cc59890654194d9ffa08e8be7cb5719833132264336.png)
Preview
5.0
11-19Yahoo FinanceArtivion Insider Offloads Shares Valued at $576,502, Per Recent SEC Disclosure
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/366ddce427ad1095fc8b55d52295aa0fb731db37e8da2eea064d486179ba8520.png)
Preview
5.0
11-15Yahoo FinanceArtivion Insider Offloads Shares Valued at $264,188, Based on Recent SEC Disclosure
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/107238eb0fef3ff3fb442315d515dc3589b24b71b1e07b1d82eddf2846bb7acf.png)
Preview
3.0
11-09Yahoo FinanceArtivion (AORT): Is the Healthcare Leader Appropriately Priced Following Recent Gains?
Sign Up For More News
People Also Watch
FAQ
What is Artivion Inc (AORT) stock price today?
What is Artivion Inc (AORT)'s business?
What is the price predicton of AORT Stock?
What is Artivion Inc (AORT)'s revenue for the last quarter?
What is Artivion Inc (AORT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Artivion Inc (AORT)'s fundamentals?
How many employees does Artivion Inc (AORT). have?